This study evaluated the effects of low-dose @entity900 plus 89Sr versus 89Sr alone in the treatment of @entity158 @entity263 , addressing both @entity158 palliation and cytostatic effects. METHODS: Seventy @entity1 with metastatic @entity263 were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m(2) @entity900 , and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the @entity1 were followed up until death to evaluate the outcome variables: grade and duration of @entity158 palliation, onset of new @entity158 sites, changes in @entity79 , global survival, serum prostate-specific antigen and alkaline phosphatase changes, and @entity1503 . RESULTS: Overall @entity158 relief occurred in 91% of @entity1 in arm A and 63% of @entity1 in arm B (P < 0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New @entity158 sites on previously asymptomatic bone @entity3 appeared in 14% of @entity1 in arm A and in 30% of @entity1 in arm B (P = 0.18). The median survival without new @entity158 sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27% of @entity1 in arm A and in 64% of @entity1 in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate @entity1503 , as determined by World Health Organization criteria, was apparent in both arms without significant differences. CONCLUSION: The addition of a low dose of @entity900 enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in @entity158 palliation and a cytostatic effect on @entity79 .

Effects of low-dose @entity900 on 89Sr therapy for XXXX @entity263 : a randomized clinical trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['hormone-refractory prostate cancer', 'bone metastases from prostate cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'painful'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity158 :: (MESH:D010146,Disease) :: ['painful']
